Wednesday, July 01, 2009

Sanofi Aventis' Lantus to be checked by EMEA

The European Medicines Agency (EMEA) has announced (PDF) that it will be investigating recently raised concerns that there may be an increased risk of cancer associated with insulin analogues, in particular insulin glargine (Lantus®).

No comments: